Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | JAK1 | P23458 | 2/20 | 0.36 |
| ▸ | TYK2 | P29597 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL954352 | 0.98 | POLB (0.57) | POLBEPHX1GBA1EPHX2NPSR1 | |
| Hydrochloric Acid SCHEMBL21639854 | 0.90 | EPHX2 (0.52) | POLBEPHX1GBA1EPHX2NPSR1 | |
| Hydrochloric Acid SCHEMBL21639853 | 0.90 | EPHX2 (0.52) | POLBEPHX1GBA1EPHX2NPSR1 | |
| SCHEMBL30473902 | 0.89 | POLB (0.77) | POLBEPHX1EPHX2KDM5A | |
| SCHEMBL21640716 | 0.89 | POLB (0.53) | POLBEPHX1EPHX2NPSR1MAPK1 | |
| Hydrochloric Acid SCHEMBL953708 | 0.89 | POLB (0.53) | POLBEPHX1EPHX2MMP2MMP8 | |
| Hydrochloric Acid SCHEMBL30473873 | 0.87 | POLB (0.74) | POLBEPHX1EPHX2KDM5A | |
| Hydrochloric Acid SCHEMBL21640754 | 0.87 | POLB (0.52) | POLBEPHX1EPHX2NPSR1MAPK1 | |
| SCHEMBL30282890 | 0.86 | POLB (0.50) | POLBEPHX1EPHX2MAPK1KDM5A | |
| SCHEMBL3330730 | 0.85 | POLB (0.64) | POLBEPHX1GBA1EPHX2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220117945-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2022-04-21 | — | — | US | disclosed |
| US-20220117945-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2022-04-21 | — | — | US | disclosed |
| EP-3601276-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF | Novartis AG (CH) | 2020-02-05 | — | — | EP | disclosed |
| CN-110461835-A | Isoxazole benzamide compound and application thereof | NOVARTIS AG | 2019-11-15 | — | — | CN | disclosed |
| WO-2018172997-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2018-09-27 | — | — | WO | disclosed |
| US-20180271837-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2018-09-27 | — | — | US | disclosed |
| US-8669266-B2 | Quinoline-carboxamide derivatives as P2Y12 antagonists | SANOFI (FR) | 2014-03-11 | — | — | US | disclosed |
| US-20110160180-A1 | Cannabinoid Receptor Ligands | ASTRAZENECA AB (SE) | 2011-06-30 | — | — | US | disclosed |
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2010-06-03 | — | — | US | disclosed |
| EP-2148871-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | Sanofi-Aventis (FR) | 2010-02-03 | — | — | EP | disclosed |
| US-20090062251-A1 | Novel Compounds 002 | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-20090062251-A1 | Novel Compounds 002 | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| WO-2009024819-A1 | CANNABINOID RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | disclosed |
| WO-2008128647-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062251-A1 | Novel Compounds 002 | OPRL1, OPRK1, OPRM1 | POLB 4496/4885EPHX1 1364/4885GBA1 606/4885 |
| US-20110160180-A1 | Cannabinoid Receptor Ligands | CNR1, CNR2, OPRL1 | POLB 4715/4885EPHX1 1309/4885GBA1 953/4885 |
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | P2RY12, P2RY1, P2RY2 | POLB 1874/4885EPHX1 428/4885GBA1 857/4885 |
| US-20180271837-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF | SLC26A4, SLC26A3, SLC8B1 | POLB 3474/4885EPHX1 2835/4885GBA1 610/4885 |
| US-20220117945-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF | SLC26A4, SLC26A3, ALDH5A1 | POLB 3318/4885EPHX1 2795/4885GBA1 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.